The study, published in Food Science of Animal Resources, used a whey-derived milk polar lipid concentrate containing at least 25 percent total phospholipids, including sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Male C57BL/6J mice, a standard strain in metabolic research, were divided into four groups of six animals each. One group received a standard control diet, a second received a high-fat high-sucrose diet deriving 43 percent of its calories from fat and 24 percent from sucrose, a third received that same obesogenic diet modified so that milk fat was replaced with 8 percent of the milk polar lipid concentrate, and a fourth received the obesogenic diet supplemented with 0.01 percent orlistat, the pancreatic lipase inhibitor sold commercially as Xenical, serving as a positive control. The animals were followed for twelve weeks, with body weight and food intake recorded weekly and body composition assessed by dual-energy X-ray absorptiometry shortly before the study’s end.

The results were striking. Mice on the high-fat high-sucrose diet gained substantially more weight than controls, but the animals receiving milk polar lipids ended the study at a final body weight statistically indistinguishable from the normal-diet group. Fat mass, measured by DEXA scanning, was significantly lower in the supplemented animals, and the treatment partially restored lean mass while also improving bone mineral content, an intriguing secondary observation that suggests the lipids may help preserve skeletal status under metabolic stress. Food and calorie intake rose gradually in the unsupplemented high-fat group, but the researchers attributed this to increasing body mass rather than heightened appetite, noting that intake did not differ across groups during the early weeks when body weights were still comparable.

Blood chemistry told a similar story of protection. The obesogenic diet drove up total cholesterol and low-density lipoprotein cholesterol, both well-established indicators of dysregulated lipid metabolism, and elevated alanine aminotransferase and aspartate aminotransferase, the two enzymes clinicians rely on most heavily to detect liver cell damage. Supplementation with the milk lipid concentrate pushed all of these markers back toward normal levels. Serum triglycerides, curiously, were actually higher in the supplemented group than in the unsupplemented high-fat group, but the authors interpret this not as a metabolic failure but as a sign of enhanced lipid mobilization and export from liver and fat stores into circulation, consistent with prior evidence that dietary phospholipids influence very-low-density lipoprotein assembly and hepatic lipid handling. They caution that the relatively short four-hour fast before tissue collection may have introduced postprandial effects and call for future studies measuring free fatty acids and hepatic VLDL secretion rates to clarify the point.

Under the microscope, the differences were unmistakable. Adipocytes in the high-fat group were markedly enlarged, a hallmark of adipose tissue dysfunction that fuels chronic low-grade inflammation and floods peripheral organs with excess free fatty acids. Both the milk lipid and orlistat groups showed significantly smaller adipocytes and reduced weights of inguinal and mesenteric white adipose tissue depots. In the liver itself, hematoxylin and eosin staining and Oil Red O staining revealed heavy fat infiltration in the high-fat group, while the supplemented animals showed dramatically reduced steatosis, lower liver weights, and significantly reduced hepatic triglyceride content. Earlier work had suggested that milk phospholipids partly work by interfering with micellar lipid solubilization in the intestine, reducing absorption and increasing fecal lipid excretion, but the tiny amounts of intact phospholipids recovered in feces in prior studies indicated the supplements themselves are efficiently absorbed, hinting that they must also act systemically after uptake.

That systemic action is where the new study makes its most technically interesting contribution. The researchers probed the hepatic Wnt/β-catenin pathway, an evolutionarily ancient signaling cascade best known for orchestrating embryonic development but increasingly recognized as a metabolic regulator. The obesogenic diet significantly suppressed key components of the pathway, reducing hepatic expression of the co-receptor LRP6 and the ligand Wnt3a. Supplementation with the milk lipids, and to a comparable degree orlistat, restored LRP6 and Wnt3a expression, but only the milk lipid diet significantly upregulated total β-catenin, the pathway’s central transcriptional effector. When Wnt signaling is active, stabilized β-catenin enters the nucleus and suppresses adipogenic transcriptional programs driven by PPARγ and C/EBPα, thereby limiting lipid storage. Consistent with that model, the supplemented animals showed significantly reduced expression of PPARγ and its downstream partners DGAT1 and PLIN2, which govern triglyceride synthesis and lipid droplet formation, along with reduced SREBP1 and the de novo lipogenesis enzymes ACC, SCD1, and FAS.

The authors propose a plausible biophysical explanation for how dietary lipids could touch this membrane-anchored pathway. Polar lipids can alter the composition of cellular membranes, and membrane phosphoinositide metabolism is known to be essential for LRP6 activation, with prior work showing that Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Milk fat globule membrane supplementation has also been shown in lipidomic studies to enrich membranes in phosphatidylcholine and phosphatidylethanolamine. In other words, the phospholipids consumed in the diet may be incorporated into hepatic membranes in ways that sensitize the Wnt machinery, though the authors are careful to frame this as a plausible mechanism rather than a demonstrated one. Notably, milk-derived sphingomyelin has previously outperformed egg-derived sphingomyelin against hepatic steatosis, suggesting that the source and molecular composition of dietary lipids matter in ways the field is only beginning to map.

The second arm of the mechanism involves the gut microbiome, and here the study employed 16S rRNA gene sequencing of cecal contents processed through the DADA2 and QIIME pipelines. The obesogenic diet significantly reduced microbial alpha diversity, as measured by the Shannon index and phylogenetic diversity, and shifted the community structure into a cluster clearly separated from controls. The milk lipid group formed its own distinct cluster, separate from both the high-fat and orlistat groups, with PERMANOVA confirming significant separation between the supplemented and unsupplemented high-fat animals. Because the orlistat group’s microbiome remained similar to the high-fat group’s, the authors infer that the lipids’ microbial effects extend beyond simple inhibition of fat absorption. At the phylum level, supplementation partially reversed the diet-driven rise in Bacillota and boosted Verrucomicrobiota, the phylum housing Akkermansia muciniphila, a mucin-degrading bacterium celebrated for its associations with gut barrier integrity and metabolic health, and consistently depleted in patients with fatty liver disease and obesity.

Additional taxa shifts reinforced the picture. The high-fat diet enriched bile acid-resistant Lactobacillus and Limosilactobacillus species, a pattern previously linked to altered intestinal bile acid composition in fatty liver models, while the milk lipid diet selectively increased Akkermansia along with Romboutsia and members of the Christensenellaceae family, taxa reported to improve lipid metabolism partly through enhanced short-chain fatty acid production. Prior studies have shown that A. muciniphila supplementation attenuates hepatic steatosis and inflammation, modulates bile acid metabolism through the intestinal FXR-FGF15 axis, and enhances mitochondrial fatty acid oxidation via L-aspartate signaling along the gut-liver axis. The authors are appropriately measured about causality, emphasizing that their microbial findings show association rather than proof and that future work measuring microbial metabolites such as short-chain fatty acids and bile acids will be needed to close the loop.

Taken together, the study sketches a coordinated mechanism in which a single dietary component acts simultaneously on intracellular lipogenic signaling and on the ecology of the gut, offering a template for how food-derived bioactives might be engineered into functional ingredients for metabolic disease. The caveats are real: the work was conducted in mice, the intervention used a concentrated extract at a dose that would be difficult to translate directly to human diets, and the mechanistic links remain partly inferential. But with fatty liver disease affecting hundreds of millions of people and no approved pharmacological therapy for its early stages, the idea that the humble membrane lipids enveloping fat droplets in milk could simultaneously quiet a liver’s fat-building program and cultivate a healthier gut community is precisely the kind of convergent finding that could shape the next generation of nutritional interventions.

Subject of Research: Effects of dietary milk polar lipids on hepatic lipid accumulation, Wnt-PPARγ signaling, and gut microbiota in a mouse model of non-alcoholic fatty liver disease

Article Title: Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota

Article References: Kim, H., Park, D., Kwon, Y.-J., & Imm, J.-Y. (2026). Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota. Food Science of Animal Resources, 46(1), Article 83. https://doi.org/10.1007/s44463-026-00100-w

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00100-w

Keywords: milk polar lipids, non-alcoholic fatty liver disease, Wnt/beta-catenin signaling, PPARgamma, gut microbiota, Akkermansia muciniphila, sphingomyelin, hepatic steatosis, short-chain fatty acids, gut-liver axis, high-fat high-sucrose diet, milk fat globule membrane

Alzheimer’s disease is the most common cause of dementia, characterized by a slow, relentless loss of memory and cognition that accompanies the accumulation of amyloid-beta peptide in the brain, the death of neurons, and the formation of tangled proteins inside cells. Although decades of research have focused on amyloid itself, the upstream molecular switches that determine whether neurons resist or succumb to these insults remain only partly understood. The new work zeroes in on one such switch: a regulatory axis connecting a long non-coding RNA, a microRNA called miR-150, and the WNT/beta-catenin pathway, a signaling system long implicated in cell survival and brain maintenance.

Long non-coding RNAs, or lncRNAs, are transcripts longer than 200 nucleotides that are not translated into proteins. Once dismissed as transcriptional noise, they are now recognized as master regulators of gene expression, capable of sponging up microRNAs, guiding protein complexes to DNA, and modulating signaling pathways. In cancer research, lncRNAs that interact with the WNT/beta-catenin pathway have been extensively characterized, but their roles in neurodegeneration are far less explored. The team behind the new study set out to determine whether one particular lncRNA, Loc646329, might influence the course of Alzheimer’s disease.

The researchers began where many modern investigations do: with publicly available human sequencing data. By analyzing datasets of brain samples from Alzheimer’s patients and healthy controls, they examined how Loc646329 and miR-150 behave in the diseased brain. The datasets, including the publicly archived GSE63501 and GSE67333 series, provided the initial evidence that these two RNA molecules are implicated in the disease state, motivating the laboratory experiments that followed.

To test the mechanism directly, the team turned to SH-SY5Y cells, a human neuroblastoma cell line widely used to model neuronal biology. Fluorescence in situ hybridization revealed that Loc646329 resides predominantly in the cytoplasm, the cellular compartment where a lncRNA would need to be if it were to interact with microRNAs. Two complementary techniques then established the physical link: AGO2-RNA immunoprecipitation, which captures RNA molecules bound to the Argonaute 2 protein at the heart of the microRNA silencing machinery, and dual-luciferase reporter assays, which confirmed that miR-150 directly targets Loc646329. Together, these experiments painted a picture of Loc646329 as a competing endogenous RNA, or molecular sponge, that sequesters miR-150 and prevents it from dampening downstream targets.

The functional consequences of this interaction were tested under brutal conditions: the cells were exposed to aggregated amyloid-beta 1-42, the toxic peptide that accumulates in Alzheimer’s brains. When Loc646329 was overexpressed, the cells fared measurably better. A battery of assays told a consistent story. CCK-8 assays showed improved metabolic viability. EdU incorporation revealed that more cells retained proliferative capacity. Annexin V-FITC/PI flow cytometry and TUNEL staining, two independent measures of programmed cell death, both showed reduced apoptosis. In other words, raising the levels of this single non-coding RNA helped neurons withstand an otherwise lethal amyloid assault.

The mechanistic core of the study lies in what happens downstream of miR-150. The WNT/beta-catenin pathway is a major regulator of neuronal survival, and its dysfunction has been repeatedly linked to Alzheimer’s disease. A key player in this pathway is GSK3beta, an enzyme whose phosphorylation status determines whether beta-catenin, the pathway’s central messenger, is stabilized and allowed to travel to the nucleus to switch on survival genes, or is tagged for destruction. The researchers found that Loc646329 overexpression increased GSK3beta phosphorylation and stabilized beta-catenin, effectively turning up the volume on WNT signaling. Critically, when the team introduced synthetic miR-150 mimics into the cells, the protective effects of Loc646329 on these signaling events were blunted, indicating that the lncRNA’s benefits depend at least partly on its ability to neutralize miR-150.

Cell culture findings, however compelling, are only a prelude to the real test: does this matter in a living brain? To find out, the researchers used APP/PS1 mice, a transgenic strain that carries human amyloid precursor protein and presenilin mutations and progressively develops amyloid plaques and memory deficits resembling Alzheimer’s disease. Using stereotaxic injection, a surgical technique that allows precise delivery of material into defined brain regions, the team introduced an adeno-associated virus carrying the Loc646329 gene directly into the animals’ hippocampus, the brain structure essential for forming new memories.

The results were striking. In the Morris water maze, a standard behavioral test in which mice must learn the location of a hidden platform using spatial cues, the treated animals found the platform more efficiently than their untreated counterparts, demonstrating improved spatial learning and memory. Biochemical and histological analysis revealed the molecular underpinnings of this improvement: the treated mice had a reduced burden of amyloid-beta plaques and increased activation of beta-catenin in the injected brain region. The study thus connected the molecular sponge hypothesis to meaningful outcomes in an intact, diseased brain, a translation that many non-coding RNA studies never achieve.

The authors are careful to frame these findings as preclinical evidence rather than a therapeutic breakthrough. The work was conducted in cell lines and in a single mouse model, and the researchers themselves note that validation in primary neurons, human-derived neuronal models, and clinical samples is required before Loc646329’s therapeutic relevance can be established. delivering RNA-based therapies to the human brain remains a formidable challenge, and microRNA networks are notoriously context-dependent, with the same microRNA sometimes producing different effects in different cell types. Nevertheless, the study adds a compelling new name to the growing roster of non-coding RNAs implicated in Alzheimer’s disease, and it strengthens the case that the WNT/beta-catenin pathway is a druggable node worth pursuing. If subsequent studies confirm that boosting Loc646329 or blocking miR-150 can safely protect human neurons, the humble sponge molecule could one day inform entirely new strategies against a disease that currently has no cure.

Subject of Research: The role of the long non-coding RNA Loc646329 in regulating Alzheimer's disease-related pathology through the miR-150/WNT/beta-catenin signaling axis.

Article Title: LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models

Article References: Abdi, K., Amiri, M., Asadalizadeh, M., Khanmirzaei, A., Javanmard, A.-R., Rezaeimirghaed, O., Hajiesmaeili, M., & Ghaderian, S. M. H. (2026). LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models. Molecular Biology Reports, 53(1), Article 1594. https://doi.org/10.1007/s11033-026-12734-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12734-6

Keywords: Alzheimer's disease, lncRNA Loc646329, miR-150, WNT/beta-catenin signaling, neurodegeneration, amyloid-beta, neuronal apoptosis, APP/PS1 mice, non-coding RNA, hippocampus, gene regulation, GSK3beta phosphorylation

The clinical backdrop to the work is well established. Epidemiological studies have repeatedly shown that patients with Parkinson’s disease face a strikingly elevated risk of osteoporosis and osteoporotic fractures, a burden that exceeds what can be explained by poor mobility, falls, or age alone. Meta-analyses cited by the researchers indicate high rates of osteoporotic fracture in Parkinson’s disease, and cross-sectional clinical work has associated biomarkers such as serum uric acid with reduced bone mineral density in affected patients. Yet the molecular mechanisms that bind neurodegeneration to bone loss have remained murky. The Henan University team set out to interrogate that relationship experimentally, asking whether a single genetic factor—absence of ACE2—could simultaneously perturb dopaminergic neuron survival in the brain and bone homeostasis in the skeleton.

To do so, the researchers used a well-characterized mouse model of parkinsonism in which the neurotoxin MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, selectively destroys dopamine-producing neurons in the substantia nigra. Crucially, they crossed this challenge with mice lacking a functional ACE2 gene—specifically Ace2-null males, designated Ace2−/y—because ACE2 sits at the center of the protective arm of the renin-angiotensin system, converting angiotensin II into angiotensin-(1–7), a peptide with documented anti-inflammatory and neuroprotective actions. Previous studies from other groups and from the same team had shown that ACE2 activation mitigates behavioral deficits and neuroinflammation in chemically induced Parkinson’s models, and that the ACE2/Ang-(1–7)/Mas cascade strengthens bone structure and metabolism. The new study asked what happens when this protective factor is removed entirely under parkinsonian stress.

Behavioral testing revealed a clear aggravating effect. MPTP exposure significantly worsened motor dysfunction and depression-like behaviors in the mice, and the combination of MPTP toxicity with ACE2 deficiency produced a particularly severe pathological picture in the brain. Immunohistochemistry, Western blotting, and histopathological staining showed reduced activity of dopaminergic neurons and heightened microglial activation—the inflammatory response of the brain’s resident immune cells. At the molecular level, the researchers measured elevated levels of total α-synuclein, the misfolding-prone protein that defines Parkinson’s pathology, alongside increased abundance of Caspase-3 and Bax, two canonical executioners of programmed cell death. Together, these markers indicate that ACE2 loss intensifies both the protein aggregation burden and the apoptotic pressure on vulnerable neurons.

The bone findings were equally striking, and notably they emerged in parallel rather than secondarily. In the skeletal tissue of the Ace2-deficient mice, the team documented reduced abundance of total Wnt ligands, β-catenin, bone morphogenetic proteins (BMP), and insulin-like growth factor 1 (IGF-1), along with diminished phosphorylation ratios of the downstream kinases that transmit these signals. This matters because each of these cascades is a cornerstone of bone formation: Wnt/β-catenin signaling drives osteoblast differentiation and bone accrual, BMPs are potent inducers of bone formation used clinically in spine fusion and fracture repair, and IGF-1 couples muscle and bone metabolism through mTOR-dependent pathways. The researchers are careful to note that the parallel reduction of these signaling proteins suggests potential perturbation of the cascades rather than definitive proof of pathway failure, a distinction that reflects appropriate scientific caution.

In the opposite direction, ACE2 deficiency upregulated mediators of the RANKL/RANK/OPG axis, a triad that governs osteoclast formation and bone resorption. RANKL binding to RANK on osteoclast precursors drives the differentiation of bone-resorbing cells, while OPG acts as a soluble decoy receptor that restrains the process. Dysregulation of this axis tilts bone turnover toward net loss. Intriguingly, the same axis operates in the brain, where it has been identified as a critical inflammatory signaling system in ischemic injury, and Rho GTPases downstream of these pathways modulate osteoclast differentiation directly. The coordinated shift of this inflammatory skeletal axis in both brain and bone tissue under ACE2 deficiency is one of the study’s most suggestive observations, hinting at a common pathological language spoken by the two organs.

To move from candidate pathways to gene-level targets, the team turned to transcriptomics. They mined public GEO datasets and applied weighted gene co-expression network analysis, or WGCNA, a computational method that groups genes into modules based on correlated expression patterns and identifies the hub genes most central to disease-associated modules. This analysis pinpointed ten hub genes, including DNM1, which encodes dynamin 1, a protein essential for synaptic vesicle recycling; OCRL, a phosphatidylinositol phosphate phosphatase linked to the oculocerebrorenal syndrome; and OPA1, a mitochondrial fusion protein whose mutations cause dominant optic atrophy and which has been implicated in mitochondrial parkinsonism through stem cell modeling. The dysregulation of these genes was linked to synaptic dysfunction and inflammation—two processes squarely at the heart of Parkinson’s pathophysiology.

The team then evaluated whether these hub genes could serve as diagnostic biomarkers. Using receiver operating characteristic, or ROC, analysis on public single-disease transcriptome datasets for Parkinson’s disease and osteoporosis separately, they found that the core gene signatures achieved areas under the curve ranging from 0.683 to 0.981, indicating diagnostic accuracy that spans moderate to near-perfect discrimination. Functional enrichment of the core genes pointed to involvement in synaptic signaling, MAPK signaling, and the Rap1 and Ras pathways—small GTPase cascades that regulate cell proliferation, differentiation, and cytoskeletal dynamics in both neurons and bone cells. Such dual-diagnostic performance, if replicated in human cohorts, would suggest that a shared molecular signature underlies both conditions and could be exploited clinically to identify patients at risk of combined neurodegenerative and skeletal decline.

The authors are appropriately measured in their claims. They emphasize that these are preclinical findings obtained under short-term MPTP treatment in growing young male mice, meaning that the observed bone metabolic disturbance was transient and that the results may not translate directly to elderly human patients, in whom Parkinson’s disease typically manifests and in whom bone loss is chronic and sex-dependent. They also stress that the coordinated dysregulation observed in brain and bone is consistent with a bone-brain axis pathological phenotype, but that the current experimental design cannot confirm causal bidirectional cross-talk between the tissues. Distinguishing whether ACE2 deficiency independently damages both organs, or whether pathology in one propagates to the other—perhaps through circulating osteocalcin, sympathetic nervous system output, or inflammatory mediators—will require interventional studies that manipulate one tissue and measure the other.

Even with those caveats, the study offers a compelling framework and a set of concrete targets for follow-up. Restoring ACE2 activity or mimicking its product, angiotensin-(1–7), has already shown neuroprotective effects in experimental Parkinson’s models, including reduced α-synuclein expression through the NEAT1/miR-153-3p axis, and ACE2 activation has been reported to promote hippocampal neurogenesis via Wnt/β-catenin signaling. The present results raise the possibility that such therapies could carry a skeletal benefit as well, protecting against the osteoporosis that so often compounds the disability of Parkinson’s disease. The ten hub genes, meanwhile, provide a molecular shortlist for mechanistic validation, and their diagnostic AUC values justify testing in human blood or tissue datasets. As the bone-brain axis matures from a descriptive concept into a mechanistic research program, work like this demonstrates how a single molecule, studied across two organs at once, can illuminate disease connections that medicine has long observed clinically but struggled to explain at the level of genes and signaling pathways.

Subject of Research: ACE2-dependent molecular mechanisms linking Parkinson's disease neurodegeneration and bone metabolic alterations via the bone-brain axis

Article Title: ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis

Article References: Liu, T., Ren, Y., Tian, X., & Wei, J. (2026). ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis. Molecular Genetics and Genomics, 301(1), Article 185. https://doi.org/10.1007/s00438-026-02511-2

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02511-2

Keywords: Parkinson's disease, ACE2, bone metabolism, bone-brain axis, osteoporosis, Wnt/beta-catenin signaling, RANKL/RANK/OPG, IGF-1, hub genes, WGCNA, alpha-synuclein, MPTP mouse model